Metagenomi Therapeutics, Inc.
MGX
$1.16
-$0.01-0.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -257.00K | 1.25M | 3.91M | 8.66M | 8.51M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -257.00K | 1.25M | 3.91M | 8.66M | 8.51M |
| Cost of Revenue | 22.51M | 19.30M | 21.50M | 25.28M | 22.51M |
| Gross Profit | -22.77M | -18.05M | -17.59M | -16.62M | -13.99M |
| SG&A Expenses | 6.00M | 6.54M | 6.78M | 6.22M | 6.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.52M | 25.84M | 28.28M | 31.50M | 29.50M |
| Operating Income | -28.77M | -24.59M | -24.37M | -22.84M | -20.99M |
| Income Before Tax | -27.48M | -23.05M | -22.49M | -20.63M | -19.86M |
| Income Tax Expenses | -- | 10.00K | 34.00K | -234.00K | 44.00K |
| Earnings from Continuing Operations | -27.48M | -23.06M | -22.53M | -20.39M | -19.91M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.48M | -23.06M | -22.53M | -20.39M | -19.91M |
| EBIT | -28.77M | -24.59M | -24.37M | -22.84M | -20.99M |
| EBITDA | -27.51M | -23.31M | -23.07M | -21.52M | -19.65M |
| EPS Basic | -0.73 | -0.61 | -0.60 | -0.55 | -0.54 |
| Normalized Basic EPS | -0.46 | -0.38 | -0.38 | -0.35 | -0.31 |
| EPS Diluted | -0.73 | -0.61 | -0.60 | -0.55 | -0.54 |
| Normalized Diluted EPS | -0.46 | -0.38 | -0.38 | -0.35 | -0.31 |
| Average Basic Shares Outstanding | 37.66M | 37.58M | 37.48M | 37.35M | 37.16M |
| Average Diluted Shares Outstanding | 37.66M | 37.58M | 37.48M | 37.35M | 37.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |